Skip to main content

Table 1 Characteristics and clinical course of patients with sepsis in the derivation and validation cohorts

From: Web-based application for predicting the potential target phenotype for recombinant human thrombomodulin therapy in patients with sepsis: analysis of three multicentre registries

Variables

Test set of the derivation cohort

(n = 1108)

Validation cohort

(n = 1184)

Predicted target patients

n = 118

Patients with rhTM target phenotype

n = 85

Predicted target patients

n = 142

Patients with rhTM target phenotype

n = 108

Age, median (IQR)

71 (56, 79)

70 (55, 79)

73 (64, 82)

73 (64, 82)

Sex, female

60 (51%)

42 (49%)

61 (43%)

45 (42%)

Body weight (kg), median (IQR)

54 (49, 63)

55 (49, 64)

55.0 (47.0, 65.0)

53.0 (46.5, 60.5)

Infection site

    

Catheter-related

2 (2%)

0 (0%)

7 (5%)

6 (6%)

Bone/soft tissue

10 (8%)

7 (8%)

11 (8%)

7 (6%)

Cardiovascular

5 (4%)

5 (6%)

5 (4%)

5 (5%)

Central nervous system

3 (3%)

3 (4%)

2 (1%)

2 (2%)

Urinary tract

28 (24%)

21 (25%)

39 (27%)

31 (29%)

Lung/thoracic

16 (14%)

13 (15%)

24 (17%)

19 (18%)

Abdomen

33 (28%)

19 (22%)

38 (27%)

25 (23%)

Other/unknown

21 (18%)

17 (20%)

16 (11%)

13 (20%)

APACHE II, median (IQR)

28 (21, 34)

27 (21, 34)

27 (22, 33)

27 (22, 32)

SIRS score, median (IQR)

3 (3, 4)

3 (3, 4)

3 (3, 4)

3 (3, 4)

SOFA scores

13 (10, 16)

13 (10, 16)

13 (11, 13)

11 (9, 14)

Lab data

    

White blood cell (103/μL), median (IQR)

11.5 (2.7, 20.3)

12.4 (2.7, 20.7)

11.0 (6.1, 20.1)

10.8 (6.3, 20.0)

Platelet (103/μL), median (IQR)

54 (29, 99)

47 (26, 76)

73 (42, 122)

68 (41, 121)

PT-INR, median (IQR)

1.7 (1.4, 2.1)

1.7 (1.4, 2.1)

1.5 (1.3, 1.7)

1.5 (1.3, 1.7)

Fibrinogen (mg/mL), median (IQR)

237 (141, 328)

220 (130, 311)

269 (153, 378)

277 (154, 381)

FDP (μg/mL), median (IQR)

98 (68, 224)

127 (80, 299)

107 (73, 188)

121 (93, 245)

D-dimer (μg/mL), median (IQR)

42 (31, 94)

51 (34, 119)

48 (32, 83)

60 (40, 106)

Antithrombin (%), median (IQR)

51 (42, 60)

50 (42, 58)

54 (48, 65)

55 (49, 66)

Lactate (mmol/L), median (IQR)

6 (3, 10)

6 (4, 10)

5 (3, 7)

5 (3, 7)

Patients who met the inclusion criteria for the SCARLET trial*

Coagulopathy

29 (25%)

23 (27%)

32 (23%)

33 (31%)

Coagulopathy and respiratory/cardiovascular dysfunction

25 (21%)

21 (25%)

27 (19%)

20 (16%)

Management

    

rhTM

52 (44%)

41 (48%)

55 (39%)

44 (44%)

Vasopressor use

105 (89%)

77 (91%)

103 (73%)

77 (71%)

Renal replacement therapy

51 (43%)

40 (47%)

23 (16%)

16 (15%)

Steroids

35 (30%)

26 (31%)

65 (48%)

48 (44%)

Intravenous immunoglobulin

58 (49%)

40 (47%)

50 (35%)

18 (17%)

Antithrombin

59 (50%)

41 (48%)

28 (20%)

22 (20%)

Prognosis

    

28-day death

48 (41%)

36 (42%)

40 (28%)

24 (25%)

In-hospital death

62 (53%)

47 (55%)

47 (33%)

28 (28%)

  1. APACHE, Acute Physiology and Chronic Health Evaluation; FDP, fibrinogen/fibrin degradation product; IQR, interquartile range; PT-INR, prothrombin time-international normalised ratio; SIRS, systemic inflammatory response syndrome; SOFA, Sequential Organ Failure Assessment; and WBC, white blood cells
  2. Five coagulation markers (in bold) were used for prediction
  3. *Defined as patients with (1) coagulopathy (PT-INR > 1.4 and platelet count 30 to 150 × 109/L) and (2) vasopressor use or mechanical ventilation use